Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › GenMark Diagnostics Receives FDA Clearance for ePlex BCID Gram-Positive Panel

GenMark Diagnostics Receives FDA Clearance for ePlex BCID Gram-Positive Panel

Dec 20, 2018
|
staff reporter

NEW YORK (GenomeWeb) – GenMark Diagnostics said today that it has received US Food and Drug Administration 510(k) clearance for its ePlex Blood Culture Identification Gram-Positive (BCID-GP) Panel.

The firm had announced toward the end of June that it applied to the FDA for market clearance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  3. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  4. Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

  5. Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.